Free Trial

111 Q3 2023 Earnings Report

111 logo
$0.88 +0.13 (+16.96%)
(As of 12/20/2024 05:31 PM ET)

111 EPS Results

Actual EPS
-$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$502.36 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here. 

111 Earnings Headlines

111, Inc. Achieves Sustained Profitability in Q3 2024
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
111, Inc. Reports Third Quarter 2024 Results
111, Inc. (YI) Q3 2024 Earnings Call Transcript
111 Net Loss Narrows In Q3, Revenues Edges Down
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI) engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

View 111 Profile

More Earnings Resources from MarketBeat

Upcoming Earnings